Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction

Leukemia volume 26, pages 1889–1892 (2012)Cite this article

Subjects

Deregulation of B-cell proliferation may induce malignant growth causing various lymphoproliferative disorders including the most prevalent hematological malignancies in adult, namely lymphoma, multiple myeloma (MM) and B-cell chronic lymphocytic leukemia.1 Inducing depletion through an apoptotic pathway or inhibiting B-cell proliferation and differentiation constitutes a rational approach to cure B-cell-mediated disorders. One such modality used recently in B-cell malignancies is rituximab, a B-cell-depleting monoclonal antibody against CD20.2 Nevertheless, efforts to identify novel therapeutic targets remain essential.

Like NK, T and antigen-presenting cells, B cells express immunoreceptor tyrosine-based inhibitory motif bearing receptors such as the leukocyte immunoglobulin-like receptor LILRB1/ILT2/CD85j.3 ILT2 is characterized by a broad specificity for HLA class-I molecules, with the highest affinity for HLA-G. However, no information is currently available on the role of ILT2 and HLA-G in regulating neoplastic B-cell growth. The biological functions of HLA-G have been originally described in maternal-fetal tolerance and more recently in allograft acceptance and tumor escape showing evidences for its tolerogenic properties.4 In contrast to classical HLA-class I, HLA-G is expressed in a limited number of healthy tissues and can be expressed as seven isoforms including four membrane-bound (HLA-G1–HLA-G4) and three soluble (HLA-G5–HLA-G7) proteins.4

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC . Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607–618.

    Article  CAS  Google Scholar 

  2. Dighiero G, Hamblin TJ . Chronic lymphocytic leukaemia. Lancet 2008; 371: 1017–1029.

    Article  CAS  Google Scholar 

  3. Colonna M, Navarro F, Bellon T, Llano M, Samaridis J, Angman L et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186: 1809–1818.

    Article  CAS  Google Scholar 

  4. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N . HLA-G: from biology to clinical benefits. Trends Immunol 2008; 29: 125–132.

    Article  CAS  Google Scholar 

  5. Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N . HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia 2008; 22: 578–584.

    Article  CAS  Google Scholar 

  6. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708–722.

    Article  CAS  Google Scholar 

  7. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008; 68: 7409–7418.

    Article  CAS  Google Scholar 

  8. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25: 1064–1079.

    Article  CAS  Google Scholar 

  9. Ketroussi F, Giuliani M, Bahri R, Azzarone B, Charpentier B, Durrbach A . Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One 2011; 6: e22776.

    Article  CAS  Google Scholar 

  10. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212–222.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by the Commissariat à l’Energie Atomique et aux energies alternatives. We thank Drs N Mooney and JC Bories for providing us with the B-cell malignant cell lines. We thank Florent Montespan and Chantal Schenowitz for technical help.

Author information

Author notes

  1. A Naji and C Menier: These authors contributed equally to this work.

Authors and Affiliations

  1. CEA, Institut des Maladies Emergentes et des Therapies Innovantes (iMETI), Service de Recherche en Hemato-Immunologie (SRHI), Hopital Saint-Louis, Paris, France

    A Naji, C Menier, G Maki, E D Carosella & N Rouas-Freiss

  2. Univ Paris Diderot, Sorbonne Paris Cite, UMR E_5 Institut Univ.Hematologie, Hopital Saint Louis, Paris, France

    A Naji, C Menier, G Maki, E D Carosella & N Rouas-Freiss

Authors
  1. A Naji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Menier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Maki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E D Carosella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Rouas-Freiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Rouas-Freiss.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naji, A., Menier, C., Maki, G. et al. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia 26, 1889–1892 (2012). https://doi.org/10.1038/leu.2012.62

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.62

This article is cited by

Search

Advanced search

Quick links